Metagenomi (NASDAQ:MGX) reported quarterly losses of $(0.51) per share which beat the analyst consensus estimate of $(0.78) by 34.62 percent. The company reported quarterly sales of $11.50 million which beat the analyst consensus estimate of $6.79 million by 69.47 percent.